Does Nabriva Therapeutics Plc – Ordinary Shares (NASDAQ:NBRV) Have Gas After Even More Sellers Involved?

March 22, 2018 - By Henry Gaston

 Does Nabriva Therapeutics Plc   Ordinary Shares (NASDAQ:NBRV) Have Gas After Even More Sellers Involved?

The stock of Nabriva Therapeutics Plc – Ordinary Shares (NASDAQ:NBRV) registered an increase of 4.77% in short interest. NBRV’s total short interest was 641,100 shares in March as published by FINRA. Its up 4.77% from 611,900 shares, reported previously. With 214,300 shares average volume, it will take short sellers 3 days to cover their NBRV’s short positions. The short interest to Nabriva Therapeutics Plc – Ordinary Shares’s float is 2.76%.

The stock increased 1.90% or $0.108 during the last trading session, reaching $5.788. About 136,986 shares traded. Nabriva Therapeutics plc (NASDAQ:NBRV) has risen 15.31% since March 22, 2017 and is uptrending. It has underperformed by 1.39% the S&P500.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. The company has market cap of $212.46 million. The Company’s lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. It currently has negative earnings. The companyÂ’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia.

Nabriva Therapeutics plc (NASDAQ:NBRV) Ratings Coverage

Among 5 analysts covering Nabriva Therapeutics (NASDAQ:NBRV), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nabriva Therapeutics has $22 highest and $10 lowest target. $15.60’s average target is 169.52% above currents $5.788 stock price. Nabriva Therapeutics had 8 analyst reports since October 12, 2015 according to SRatingsIntel. RBC Capital Markets initiated it with “Outperform” rating and $21 target in Tuesday, October 13 report. The stock of Nabriva Therapeutics plc (NASDAQ:NBRV) has “Buy” rating given on Wednesday, January 27 by Gabelli. The firm has “Outperform” rating given on Tuesday, October 13 by Wedbush. On Thursday, November 12 the stock rating was maintained by RBC Capital Markets with “Outperform”. Leerink Swann reinitiated the shares of NBRV in report on Thursday, October 27 with “Outperform” rating. Needham initiated the stock with “Buy” rating in Monday, October 12 report. As per Wednesday, February 1, the company rating was maintained by Wedbush. The stock of Nabriva Therapeutics plc (NASDAQ:NBRV) earned “Outperform” rating by Leerink Swann on Tuesday, October 13.

More notable recent Nabriva Therapeutics plc (NASDAQ:NBRV) news were published by: which released: “Nabriva Therapeutics Announces Proposed Public Offering of Ordinary Shares” on September 18, 2017, also with their article: “Nabriva Announces the Proposed Redomicile of its Holding Company from Austria …” published on April 17, 2017, published: “Nabriva Therapeutics plc Successfully Concludes Tender Offer for Outstanding …” on June 26, 2017. More interesting news about Nabriva Therapeutics plc (NASDAQ:NBRV) were released by: and their article: “Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate …” published on March 16, 2018 as well as‘s news article titled: “Nabriva Commences Previously Announced Tender Offer Related to the Proposed …” with publication date: May 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: